NEW YORK (GenomeWeb) – Cancer diagnostics firm Biodesix has raised $8.6 million in promissory notes, according to a document filed recently with the US Securities and Exchange Commission.

The firm disclosed that it seeks to raise up to $20 million and that it has so far raised $8.6 million in promissory notes convertible into equity securities.

The firm did not disclose what it would use the funds for or the identities of the investors in the financing. It said that 18 investors have participated in the financing. Biodesix did not respond to requests seeking comment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.